Capricor Therapeutics (NASDAQ:CAPR) Sees Large Volume Increase – Still a Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw unusually-strong trading volume on Thursday . 3,479,674 shares changed hands during mid-day trading, an increase of 17% from the previous session’s volume of 2,965,967 shares.The stock last traded at $10.4050 and had previously closed at $9.36.

Capricor Therapeutics News Roundup

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Oppenheimer upgraded Capricor to Outperform, providing a bullish Wall Street signal that may support the stock and partially counter ongoing legal concerns. Capricor Therapeutics Raised to Outperform at Oppenheimer
• Neutral Sentiment: Unusually high call-option activity was reported on August 25, with 18,509 calls purchased—about 190% above typical volume. This may indicate bullish speculation or hedging, but it does not confirm a sustained share-price recovery.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Capricor and certain executives. The lawsuit alleges that management’s statements about the Phase 3 HOPE-3 trial failed to disclose changes to the study’s pre-specified statistical analysis plan that allegedly lacked FDA agreement. Plaintiffs claim the FDA later characterized related results as “post-hoc and exploratory.” The allegations have not been proven. SueWallSt Capricor securities class action deadline
• Negative Sentiment: The repeated notices highlight a September 28, 2026 deadline for investors to seek lead-plaintiff status. Although the deadline itself does not create a direct financial liability, the volume of announcements reinforces concerns about potential litigation costs, management credibility, FDA compliance, and the commercial prospects of Capricor’s lead programs. Capricor class action lawsuit deadline
• Negative Sentiment: Investor-rights firms also pointed to Capricor’s recent second-quarter earnings call, which reportedly omitted a management question-and-answer session with analysts. That unusual format may increase uncertainty around the company’s trial results, regulatory strategy, and response to the litigation. Capricor Q2 earnings and securities class action

Analysts Set New Price Targets

A number of analysts have recently commented on the company. B. Riley Financial cut Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 target price on the stock. in a research report on Monday, July 27th. Wall Street Zen downgraded Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Alliance Global Partners downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a report on Tuesday, July 28th. Finally, Oppenheimer upgraded shares of Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Capricor Therapeutics has an average rating of “Hold” and an average price target of $29.15.

Capricor Therapeutics Stock Performance

The stock has a market capitalization of $597.62 million, a PE ratio of -4.19 and a beta of 0.54. The business’s 50-day moving average is $15.20 and its two-hundred day moving average is $24.51.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). Equities analysts forecast that Capricor Therapeutics, Inc. will post -1.65 EPS for the current year.

Insider Buying and Selling

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the sale, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. The trade was a 68.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 25,000 shares of company stock valued at $759,158 in the last three months. 9.20% of the stock is owned by company insiders.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently modified their holdings of the business. Suvretta Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth $51,533,000. Tang Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $49,062,000. RA Capital Management L.P. acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $43,516,000. California State Teachers Retirement System lifted its stake in shares of Capricor Therapeutics by 2,261.8% in the second quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company’s stock valued at $36,806,000 after purchasing an additional 1,463,762 shares during the period. Finally, Darwin Global Management Ltd. purchased a new stake in Capricor Therapeutics during the fourth quarter worth about $23,168,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.